DHLAX | DOXGX | DHLAX / DOXGX | |
Total Expense Ratio | 0.96 | 0.41 | 234% |
Annual Report Gross Expense Ratio | 0.96 | 0.46 | 209% |
Fund Existence | 24 years | 3 years | - |
Gain YTD | 5.057 | 8.021 | 63% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 2500 | 100% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 8.43B | 117B | 7% |
Annual Yield % from dividends | 1.04 | 1.47 | 71% |
Returns for 1 year | -0.97 | 6.86 | -14% |
Returns for 3 years | 15.76 | 31.09 | 51% |
Returns for 5 years | 33.96 | N/A | - |
Returns for 10 years | 59.28 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
PARWX | 57.32 | 0.30 | +0.53% |
Parnassus Value Equity Investor | |||
GILLX | 23.90 | 0.10 | +0.42% |
Goldman Sachs Enhanced U.S. Equity Inst | |||
VECRX | 22.33 | 0.07 | +0.31% |
Virtus KAR Equity Income R6 | |||
NZDCHF | 0.48 | 0.00 | +0.21% |
New Zealand Dollar - Switzerland Franc | |||
FBTIX | 30.97 | N/A | N/A |
Fidelity Advisor Biotechnology I |